Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 2 Trials for Pazopanib (DB06589)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00454142Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal CancerTreatment